Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent

INTRODUCTION: Coronary bifurcations are encountered in about 15% to 20% of percutaneous coronary interventions (PCIs). They are considered technically challenging and associated with worse clinical outcomes than nonbifurcation lesions. The BiOSS LIM C is a dedicated bifurcation balloon expandable st...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil, Robert J., Pawłowski, Tomasz, Legutko, Jacek, Lesiak, Maciej, Witkowski, Adam, Gąsior, Mariusz, Kern, Adam, Bil, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455659/
https://www.ncbi.nlm.nih.gov/pubmed/30946377
http://dx.doi.org/10.1097/MD.0000000000015106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455659/
https://www.ncbi.nlm.nih.gov/pubmed/30946377
http://dx.doi.org/10.1097/MD.0000000000015106

Ejemplares similares